VolitionRx Limited (VNRX)
| Market Cap | 29.29M |
| Revenue (ttm) | 1.47M |
| Net Income (ttm) | -22.88M |
| Shares Out | 137.52M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,299,511 |
| Open | 0.240 |
| Previous Close | 0.235 |
| Day's Range | 0.212 - 0.243 |
| 52-Week Range | 0.170 - 0.940 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 2.50 (+1,073.71%) |
| Earnings Date | Mar 30, 2026 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment r... [Read more]
Financial Performance
In 2024, VolitionRx's revenue was $1.23 million, an increase of 59.10% compared to the previous year's $775,302. Losses were -$26.97 million, -23.65% less than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price target is $2.5, which is an increase of 1,073.71% from the latest price.
News
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
HENDERSON, Nev., Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significa...
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratori...
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
HENDERSON, Nev., Feb. 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026, it...
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
Showing New Indication for Nu.Q® NETs HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsors...
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submiss...
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Nu.Q® Biomarker Paper Available on MedRXIV HENDERSON, Nev., Jan. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the rel...
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory ...
Volition Sponsors Symposium at Veterinary Meeting and Expo
HENDERSON, Nev., Jan. 16, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of an industry symposium at the wo...
VolitionRx Secures $2.0 Million in Funding
HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into an ...
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epi...
Volition Issues Business Review 2025
HENDERSON, Nev. , Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025.
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
HENDERSON, Nev. , Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitle...
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North...
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
HENDERSON, Nev. , Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay i...
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
HENDERSON, Nev. , Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays t...
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript
VolitionRx Limited ( VNRX) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Louise Batchelor Day - Group Chief Marketing & Communications Officer Cameron Reynolds - Founder, C...
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada , Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE...
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
Conference call to take place on Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
HENDERSON, Nev. , Oct. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), and its subsidiary, Volition Veterinary Diagnostics Development LLC, in line with their corporate...
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
HENDERSON, Nev. , Oct. 10, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwri...
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
HENDERSON, Nev. , Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to off...
VolitionRx Limited - Special Call
VolitionRx Limited - Special Call Company Participants Marielle Herzog Conference Call Participants Alexandra Byrne Eric Ariazi Presentation Alexandra Byrne Great. Good morning, everyone.
Volition Sponsors Upcoming GenomeWeb Webinar
HENDERSON, Nev. , Oct. 2, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the sponsorship of a GenomeWeb webinar entit...
Volition Signs Co-Marketing and Services Agreement with Hologic
HENDERSON, Nev. , Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Holog...
Volition Signs First Human Out Licensing Deal
HENDERSON, Nev. , Sept. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the signing of a Research License and Exclu...